Research Analysts Issue Forecasts for Imunon Q1 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Research analysts at Brookline Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for shares of Imunon in a research note issued to investors on Friday, June 5th. Brookline Capital Markets analyst K. Dolliver expects that the company will post earnings per share of ($0.81) for the quarter. The consensus estimate for Imunon’s current full-year earnings is ($3.69) per share. Brookline Capital Markets also issued estimates for Imunon’s Q2 2027 earnings at ($0.78) EPS, Q3 2027 earnings at ($0.78) EPS and Q4 2027 earnings at ($0.75) EPS.

A number of other equities research analysts have also recently weighed in on the company. Maxim Group set a $10.00 price target on Imunon and gave the company a “buy” rating in a report on Friday, April 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Imunon currently has an average rating of “Hold” and a consensus target price of $10.00.

Imunon Price Performance

IMNN stock opened at $2.01 on Tuesday. The business has a fifty day moving average price of $2.67 and a 200 day moving average price of $3.20. Imunon has a fifty-two week low of $1.96 and a fifty-two week high of $27.65. The stock has a market capitalization of $8.44 million, a price-to-earnings ratio of -0.39 and a beta of 1.95.

Imunon (NASDAQ:IMNN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.38.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IMNN. Riverview Capital Advisers LLC lifted its holdings in Imunon by 193.3% during the 3rd quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock worth $176,000 after buying an additional 22,649 shares in the last quarter. DRW Securities LLC lifted its holdings in Imunon by 6.9% during the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock worth $224,000 after buying an additional 3,803 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in Imunon during the 4th quarter worth $1,017,000. Institutional investors and hedge funds own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.